ArticleOpen forum infectious diseases2022

A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019.

Jin Yong Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.